N-(biphenyl-4-ylmethyl)-5-hydroxy-2-methyl-4-oxo-4H-pyran-3-carboxamide

ID: ALA525733

Chembl Id: CHEMBL525733

PubChem CID: 16726687

Max Phase: Preclinical

Molecular Formula: C20H17NO4

Molecular Weight: 335.36

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Cc1occ(O)c(=O)c1C(=O)NCc1ccc(-c2ccccc2)cc1

Standard InChI:  InChI=1S/C20H17NO4/c1-13-18(19(23)17(22)12-25-13)20(24)21-11-14-7-9-16(10-8-14)15-5-3-2-4-6-15/h2-10,12,22H,11H2,1H3,(H,21,24)

Standard InChI Key:  SQICDVOXCYHCFG-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA525733

   5-hydroxy-2-methyl-4-oxo-N-[(4-phenylphenyl)methyl]pyran-3-carboxamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 335.36

Molecular Weight (Monoisotopic): 335.1158

AlogP: 3.25

#Rotatable Bonds: 4

Polar Surface Area: 79.54

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 9.02

CX Basic pKa: ┄

CX LogP: 2.92

CX LogD: 2.91

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.77

Np Likeness Score: -0.35

References

1. Yan YL, Miller MT, Cao Y, Cohen SM..  (2009)  Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.,  19  (7): [PMID:19261472] [10.1016/j.bmcl.2009.02.044]

2. Arshad JZ, Hanif M..  (2022)  Hydroxypyrone derivatives in drug discovery: from chelation therapy to rational design of metalloenzyme inhibitors.,  13  (10.0): [PMID:36325396] [10.1039/d2md00175f]

Source

Source(1):

• Scientific Literature